目前韩国对COVID-19后综合征的理解主要基于调查研究或针对特定患者群体的研究,比如住院的人。此外,大多数相关研究是在欧洲和北美人群中进行的,这可能会限制它们在韩国背景下的适用性。为了解决这个差距,我们的研究探讨了COVID-19的一年结局,重点是韩国潜在的急性后综合征和全因死亡率.
■这项回顾性队列研究使用了韩国的全国性索赔数据,包括年龄>18岁的成年人,记录在2020年1月20日至2021年2月25日之间。患者分为COVID-19和非COVID-19组,并根据倾向评分1:1匹配。主要结果是急性COVID-19综合征后12个月和全因死亡率。
■该研究涉及34,802名匹配患者。COVID-19组的凝血功能障碍风险显著升高(OR=2.70[2.24,3.28];p<0.001),慢性下呼吸道疾病(OR=1.96[1.80,2.14];p<0.001),循环系统和呼吸系统的症状(OR=1.91[1.80,2.04];p<0.001),情绪障碍(OR=1.67[1.51,1.86];p<0.001),心脏病(OR=1.39[1.21,1.59];p<0.001),和认知症状,感知,情绪状态,和行为(OR=1.15[1.04,1.27];p=0.005)。在6个月期间,COVID-19组的全因死亡率较高(OR=1.34[1.06,1.69];p=0.015),但逐渐减少,在1年时达到0.996的OR([0.83,1.19];p=0.964)。
■在韩国,急性COVID-19综合征后12个月包括凝血功能障碍,呼吸问题,情绪障碍,和心脏疾病。新冠肺炎后全因死亡的风险增加长达6个月,然后显着减少,并在一年内解决。
UNASSIGNED: Current understanding of post-COVID-19 syndrome in South Korea is primarily based on survey studies or research targeting specific patient groups, such as those hospitalized. Moreover, the majority of relevant studies have been conducted in European and North American populations, which may limit their applicability to the South Korean context. To address this gap, our study explores the one-year outcomes of COVID-19, focusing on the potential post-acute syndrome and all-cause mortality in South Korea.
UNASSIGNED: This retrospective cohort study used nationwide claims data in South Korea, including adults aged >18 with records between January 20, 2020, and February 25, 2021. Patients were classified into COVID-19 and non-COVID-19 groups and matched 1:1 based on propensity scores. Primary outcomes were 12-month post-acute COVID-19 syndrome and all-cause mortality.
UNASSIGNED: The study involved 34,802 matched patients. The COVID-19 group had significantly elevated risks of coagulopathies (OR = 2.70 [2.24, 3.28]; p < 0.001), chronic lower respiratory diseases (OR = 1.96 [1.80, 2.14]; p < 0.001), symptoms of the circulatory and respiratory systems (OR = 1.91 [1.80, 2.04]; p < 0.001), mood disorders (OR = 1.67 [1.51, 1.86]; p < 0.001), cardiac diseases (OR = 1.39 [1.21, 1.59]; p < 0.001), and symptoms of cognition, perception, emotional state, and behavior (OR = 1.15 [1.04, 1.27]; p = 0.005). All-cause mortality was higher in the COVID-19 group during the 6 months (OR = 1.34 [1.06, 1.69]; p = 0.015), but gradually decreased, reaching an OR of 0.996 ([0.83, 1.19]; p = 0.964) at 1 year.
UNASSIGNED: In South Korea, the 12-month post-acute COVID-19 syndrome includes coagulopathies, respiratory issues, mood disorders, and cardiac diseases. The risk of all-cause mortality post-COVID-19 is heightened for up to 6 months, then significantly decreases and resolves within a year.